Trial Profile
A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion (CRVO)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 May 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms LEAVO
- 01 Jul 2020 Results mappings to convert best-corrected visual acuity (BCVA) to the EQ-5D-3L, the EQ-5D-3L with a vision bolt-on (EQ-5D V), and the Visual Functioning Questionnaire-Utility Index (VFQ-UI), published in the Value in Health.
- 06 Nov 2019 Data from this study were used for cost-utility comparison of ranibizumab versus aflibercept versus bevacizumab presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 06 Nov 2019 Results developing mappings to predict utilities beyond the study period using better-(BSE) and worse-seeing eye (WSE) BCVA, age and sex presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research